Trojan horses encapsulated by a TRODELVYᵀᴹ cell membrane in a green, cellular environment.



  • Triple-negative breast cancer (TNBC) tumor cells lack HR receptors and also don’t make too much of the HER2 protein, leaving limited available treatment options1,2
  • Following first-line treatment for mTNBC, published response rates with subsequent treatments have historically been poor2

mTNBC remains the most aggressive and hard-to-treat breast cancer subtype1

  • TNBC is often associated with visceral metastases1
  • TNBC accounts for approximately 15% of all breast cancers3 and is associated with aggressive tumor biology and a poor prognosis1,2
  • When comparing age groups, the majority of TNBC cases are diagnosed in women 51-60 years old4
    • If a patient develops breast cancer before age 40, it is more likely to be TNBC than in women who develop breast cancer after age 404
  • A higher proportion of African American and Hispanic women who develop breast cancer have the TNBC subtype compared with Caucasian women diagnosed with breast cancer1,4,5
  • If breast cancer develops in people with germline BRCA mutation (either BRCA1 or BRCA2), it is more likely to be TNBC2,6
    • Other risk factors for the disease include premenopausal status, obesity, and maternal-related factors such as parity and age at first pregnancy7
References: 1. Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12(2):106-116. 2. André F, Zielinski CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 2012;23 (Suppl 6):vi46-vi51. 3. Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107(6): djv048. 4. Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chapar AB, Lannin DR. Features of triple-negative breast cancer: analysis of 38,813 cases from the national cancer database. Medicine (Baltimore). 2016;95(35):e4614. 5. Breast Cancer Hormone Receptor Status. American Cancer Society website. Accessed November 30, 2020. 6. Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Sub-typing of triple-negative breast cancer: implications for therapy. Cancer. 2015;121(1):8-16. 7. Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009; 20(7):1071-1082.